PMID- 11989522
OWN - NLM
STAT- MEDLINE
DCOM- 20020523
LR  - 20190916
IS  - 0959-4973 (Print)
IS  - 0959-4973 (Linking)
VI  - 12 Suppl 4
DP  - 2001 Dec
TI  - Maximizing the response to Herceptin therapy through optimal use and patient 
      selection.
PG  - S11-7
AB  - The aggressiveness of human epidermal growth factor receptor-2 (HER2)-positive 
      breast cancer and the poor prognosis of women with this disease demand the 
      availability of accurate and reliable tests for HER2 status and the optimization 
      of HER2-targeted therapy. The distinctive clinical pattern of HER2-positive 
      breast cancer underlines the importance of testing for HER2 status and efforts 
      are ongoing to validate the two major methods in use-immunohistochemistry (IHC), 
      which measures cell membrane HER2 expression, and fluorescence in situ 
      hybridization (FISH), which measures gene copy number. Clinical trial results 
      demonstrate that there is an association between strong HER2 overexpression (IHC 
      3+) and optimal response to therapy with the novel recombinant HER2 antibody 
      Herceptin. High levels of concordance between IHC 3+ and FISH-positive status 
      have been observed, and response to treatment with Herceptin is similar for 
      patients whose breast cancers are IHC 3+ and those who are FISH-positive. 
      Observations to date have led to the formulation of an algorithm for HER2 status 
      determination and Herceptin use which recommends that: (i) the HER2 status of all 
      women with breast cancer be determined at presentation, (ii) all IHC 3+ and 
      FISH-positive patients with metastatic disease should receive Herceptin, (iii) 
      Herceptin should be used early in the course of metastatic breast cancer and 
      preferably first line, and (iv) Herceptin therapy should be continued until 
      disease progression.
FAU - Leyland-Jones, B
AU  - Leyland-Jones B
AD  - Department of Oncology, McGill University, Montreal, Quebec, Canada. 
      leylandj@med.mcgill.ca
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - *Patient Selection
MH  - Receptor, ErbB-2/metabolism
MH  - Trastuzumab
RF  - 53
EDAT- 2002/05/07 10:00
MHDA- 2002/05/25 10:01
CRDT- 2002/05/07 10:00
PHST- 2002/05/07 10:00 [pubmed]
PHST- 2002/05/25 10:01 [medline]
PHST- 2002/05/07 10:00 [entrez]
AID - 10.1097/00001813-200112004-00003 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2001 Dec;12 Suppl 4:S11-7. doi: 
      10.1097/00001813-200112004-00003.